Your browser version may not work well with NCBI's Web applications. More information here...
1: Pediatr Nephrol. 2008 Apr;23(4):611-8. Epub 2008 Jan 18.
Related Articles, Links
Click here to read Click here to read
In vivo mesna and amifostine do not prevent chloroacetaldehyde nephrotoxicity in vitro.

Yaseen Z, Michoudet C, Baverel G, Dubourg L.

INSERM U820, Métabolomique et Maladies Métaboliques, Faculté Laennec, Lyon Cedex 08, France.

Chloroacetaldehyde (CAA) is the putative metabolite responsible for ifosfamide-induced nephrotoxicity. Whereas evidence suggests that sodium 2-mercaptoethanesulfonate (mesna) and amifostine protect renal cells against CAA toxicity in vitro, their efficacy in clinical studies is controversial. To better understand the discrepancy between in vivo and in vitro results, we combined the in vivo intraperitoneal administration of either saline or mesna (100 mg/kg) or amifostine (200 mg/kg) in rats and the in vitro study of CAA toxicity to both proximal tubules and precision-cut renal cortical slices. The measured renal cortical concentrations of mesna and amifostine were 0.6+/-0.1 micromol/g and 1.2+/-0.2 micromol/g, respectively; these drugs did not cause renal toxicity. Despite this, none of the adverse effects of 0.5 mM CAA was prevented by the previous in vivo administration of mesna or amifostine. Toxicity of 0.5 mM CAA to rat proximal tubules was shown by the fall of cellular adenosine triphosphate (ATP), total glutathione and coenzyme A + acetyl-coenzyme A levels and by the altered metabolic viability of renal cells. Long-term exposure of cortical slices to CAA concentrations > or =30 microM caused severe cell toxicity (i.e. decrease in cellular ATP, total glutathione, and coenzyme A + acetyl-coenzyme A levels), which was not prevented by the in vivo administration of mesna or amifostine.

Publication Types:
PMID: 18204866 [PubMed - indexed for MEDLINE]